chapter  8
20 Pages

Routes and Formulations for Delivery of Antisense Oligonucleotides

WithGregory E. Hardee, Lloyd G. Tillman, Richard S. Geary

Initial efforts in the creation of antisense therapeutics have focused on fundamental questions such as safety, efficacy, and technology costs, as would be expected for any emerging technology with a potential to create a new therapeutic paradigm. Clinical proof of efficacy has been established with the approval of the first antisense oligonucleotide therapeutic, Vitravene™ (fomivirsen), indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with AIDs [1].